Emily O'Brien

Dr. Emily O'Brien


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2025 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
EOEmily O'Brien
Emily O'Brien
CMChristopher M. Mayer
Christopher M. Mayer
RARebecca C Arend
Rebecca C Arend
• T-Cell bispecific antibodies bind tumor and T-cells, forming an immune synapse that activates and proliferates T-Cells, leading to tumor death. • Preclinical studies show TCBs can target AXL, MUC1, LYPD1, and MUC16 effectively in gynecologic cancers. • The safety concerns with TCBs include cytokine release syndrome and off-tumor toxicity, requiring careful monitoring and management in patients. • TCBs represent a promising immunotherapy approach for gynecologic cancers, supporting the need for continued research and clinical trials.

12 January 2026 in Targets
Verified
Journal Article
Open access
PDF file
EOEmily O'Brien
Emily O'Brien
DDDhruva Mitul Dave
Dhruva Mitul Dave
AKAbbie Kleckley
Abbie Kleckley
FOFibiana Oladipo
Fibiana Oladipo
CMChristopher M. Mayer
Christopher M. Mayer
RARebecca Arend
Rebecca Arend
Background/Objectives: This pilot study investigates the feasibility of using patient-derived microtumors (PDMs) to assess chemotherapy response in epithelial ovarian cancer. Methods: Fresh tissue from 10 patients was used to develop PDMs, which were then tested against carboplatin/paclitaxel, carboplatin/docetaxel, and carboplatin/pegylated liposomal doxorubicin (PLD). Of the 10 PDMs, 3 were obtained from primary debulking surgery (PDS), and 7 were obtained at the time of interval debulking surgery following neoadjuvant chemotherapy. Results: When looking at PDMs derived from tissue collected at the time of PDS, we found that 100% of PDMs demonstrated a full response to carboplatin/PLD, while 30% showed a full response to all regimens, all of which were derived from high-grade serous carcinoma during PDS. The remaining PDMs showed moderate responses to carbo/taxol and carbo/doce. Conclusions: This study suggests that PDMs can be used to assess the efficacy of chemotherapy regimens, as a hypothesis-generating step toward future predictive validation.